N- ((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3 - (7-tert-butylpyrazolo[1,5-a][1,3,5]triazin4-ylamino)-2-oxopyrrolidin-1-yl)cyclohe xyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

Details for Australian Patent Application No. 2010306968 (hide)

Owner Bristol-Myers Squibb Company

Inventors Carter, Percy H.; Cherney, Robert J.; Rosso, Victor W.; Li, Jun

Agent A J Park

Pub. Number AU-A-2010306968

PCT Pub. Number WO2011/046916

Priority 61/250,978 13.10.09 US

Filing date 12 October 2010

Wipo publication date 21 April 2011

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

Event Publications

3 May 2012 PCT application entered the National Phase

  PCT publication WO2011/046916 Priority application(s): WO2011/046916

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010306971-Sunscreen compositions

2010306964-Systems and methods for synchronized control of electrical power system voltage profiles